Schering ends Melacine comarketing agreement
Executive Summary
Corixa is looking for comarketing partner for melanoma vaccine Melacine after Schering-Plough bows out of their sales and marketing agreement July 31. Schering's decision comes five months after an FDA Oncologic Drugs Advisory Committee recommended that Melacine undergo a second Phase III trial with relapse free survival as a primary endpoint (1"The Pink Sheet" March 4, p 31)...
You may also be interested in...
Melacine Relapse-Free Survival Endpoint Could Give Inconclusive Result
Use of relapse-free survival as a primary endpoint in studies of Corixa's melanoma vaccine Melacine would produce an ambiguous efficacy result, FDA's Oncologic Drugs Advisory Committee suggested
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.